“Neutral” was Maintained on Mallinckrodt (NYSE:MNK) by B. Riley FBR; with $20 Target.

June 29, 2018 - By Mary Bollinger

During Q1 2018 the big money sentiment increased to 0.9. That’s change of 0.19, from 2017Q4’s 0.71. 38 investors sold all, 85 reduced holdings as Mallinckrodt Public Limited Company ratio improved. 64 grew positions while 47 funds amassed positions. Funds hold 96.44 million shares thus 6.30% more from 2017Q4’s 90.73 million shares.

California State Teachers Retirement holds 0% or 154,115 shs in its capital. Ls Advsr Limited Liability Corporation reported 0% stake. Legal General Grp Public Ltd reported 161,857 shs or 0% of all its holdings. Oregon Public Employees Retirement Fund invested in 0.01% or 35,755 shs. Peak6 Invests L P accumulated 18,852 shs or 0% of the stock. Jacobs Levy Equity Management Inc accumulated 83,700 shs or 0.02% of the stock. San Francisco Sentry Invest Group (Ca) has 5 shs. Continental Advsrs Lc has invested 0.15% in Mallinckrodt Public Limited Company (NYSE:MNK). 43,371 are held by Mason Street Lc. Victory Capital Mgmt has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Old Second State Bank Of Aurora invested 0% of its capital in Mallinckrodt Public Limited Company (NYSE:MNK). Germany-based Commerzbank Aktiengesellschaft Fi has invested 0.02% in Mallinckrodt Public Limited Company (NYSE:MNK). Advsr Asset Mgmt Inc stated it has 0% of its capital in Mallinckrodt Public Limited Company (NYSE:MNK). 2,671 are held by Point72 Asia (Hong Kong) Limited. Art Advisors Limited Liability reported 74,081 shs.

Mallinckrodt Public Limited Company registered $4.14 million net activity with 1 insider buy and 1 insider sale since May 9, 2018. On Wednesday, May 16 Shares for $46,615 were bought by Trudeau Mark.

Reiterated Mallinckrodt (NYSE:MNK) Rating.

The $20 target price per share on the $1.55 billion MC company given by Professional analysts at B. Riley FBR means a potential upside of 7.18 %. The Mallinckrodt (NYSE:MNK)‘s stock had its “Neutral” Rating issued to investors and clients in a research report on Thursday, 28 June.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

In total 12 analysts cover Mallinckrodt (NYSE:MNK). “Buy” rating has 4, “Sell” are 1, while 7 are “Hold”. (NYSE:MNK) has 33% bullish analysts. 22 are the (NYSE:MNK)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Tuesday, February 6 BMO Capital Markets maintained Mallinckrodt Public Limited Company (NYSE:MNK) with “Buy” rating. On Tuesday, February 27 the firm has “Hold” rating by Mizuho given. On Monday, April 2 the firm has “Buy” rating by Cantor Fitzgerald given. On Tuesday, May 8 the stock of Mallinckrodt Public Limited Company (NYSE:MNK) has “Buy” rating given by Cantor Fitzgerald. On Wednesday, May 9 the company was maintained by Morgan Stanley. On Friday, March 9 Mizuho maintained the shares of MNK in report with “Hold” rating. On Friday, February 2 Barclays Capital downgraded Mallinckrodt Public Limited Company (NYSE:MNK) to “Underweight” rating. In Thursday, April 12 report Stifel Nicolaus downgraded the stock to “Hold” rating. In Tuesday, March 6 report Canaccord Genuity maintained the stock with “Hold” rating. In Tuesday, January 9 report Mizuho maintained it with “Hold” rating and $21.0 target.

Ticker’s shares touched $18.66 during the last trading session after 2.71% change.Currently Mallinckrodt Public Limited Company is downtrending after 59.76% change in last June 29, 2017. MNK has also 1.25M shares volume. MNK underperformed the S&P500 by 72.33%.

Mallinckrodt Public Limited Company (NYSE:MNK)’s earnings report is awaited on August, 14., according to Zacks. Analysts expect change of 19.46 % or $0.36 from previous year’s $1.85 EPS compared to current’s $1.49 EPS. If MNK’s EPS is $1.49 the profit will reach $123.77M for 3.13 P/E. After $1.31 EPS report last quarter, Wall Street now predicts 13.74 % EPS growth of Mallinckrodt Public Limited Company.

Mallinckrodt public limited company develops, makes, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions.The company has $1.55 billion market cap. The firm markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.1.02 is the P/E ratio. It offers H.P.

More recent Mallinckrodt Public Limited Company (NYSE:MNK) news were announced by Seekingalpha.com, Streetinsider.com and Streetinsider.com. The first one has “Mallinckrodt: The Cheapest Stock In Global Healthcare” as a title and was announced on June 08, 2018. The next is “Mallinckrodt (MNK) Reports Complete Enrollment Target for Rheumatoid Arthritis Phase 4 Clinical Study for HP Acthar …” on June 28, 2018. And last was announced on June 28, 2018, called “Aurobindo Said in Advanced Talks to buy Mallinckrodt’s (MNK) Specialty Generics Business – CNBC-TV18”.

Mallinckrodt Public Limited Company (NYSE:MNK) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: